CoChat

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

Open access
On behalf of the European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), Cornelissen, D., de Kunder, S., Si, L., Reginster, J.-Y., Evers, S., Boonen, A., Hiligsmann, M. · 2020 · Osteoporosis International
Cited by 101

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

An earlier systematic review on interventions to improve adherence and persistence was updated. Fifteen studies investigating the effectiveness of patient education, drug regimen, monitoring and supervision, and interdisciplinary collaboration as a single or multi-component intervention were appraised. Multicomponent interventions with active patient involvement were more effective. INTRODUCTION: This study was conducted to update a systematic literature review on interventions to improve adherence to anti-osteoporosis medications. METHODS: A systematic literature review was carried out in Medline (using PubMed), Embase (using Ovid), Cochrane Library, Current Controlled Trials, ClinicalTrials.gov , NHS Centre for Review and Dissemination, CINHAL, and PsycINFO to search for original studies that assessed interventions to improve adherence (comprising initiation, implementation, and discontinuation) and persistence to anti-osteoporosis medications among patients with osteoporosis, published between July 2012 and December 2018. Quality of included studies was assessed. RESULTS: Of 585 studies initially identified, 15 studies fulfilled the inclusion criteria of which 12 were randomized controlled trials. Interventions were classified as (1) patient education (n = 9), (2) drug regimen (n = 3), (3) monitoring and supervision (n = 2), and (4) interdisciplinary collaboration (n = 1). In most subtypes of interventions, mixed results on adherence (and persistence) were found. Multicomponent interventions based on patient education and counseling were the most effective interventions when aiming to increase adherence and/or persistence to osteoporosis medications. CONCLUSION: This updated review suggests that patient education, monitoring and supervision, change in drug regimen, and interdisciplinary collaboration have mixed results on medication adherence and persistence, with more positive effects for multicomponent interventions with active patient involvement. Compared with the previous review, a shift towards more patient involvement, counseling and shared decision-making, was seen, suggesting that individualized solutions, based on collaboration between the patient and the healthcare provider, are needed to improve adherence and persistence to osteoporosis medications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00198-020-05378-0

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 40

  1. Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8. https://doi.org/10.1007/s11657-013-0136-1 · DOI · Paper page
  2. Lötters FJB, van den Bergh JP, de Vries F et al (2016) Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int 98:235–243. https://doi.org/10.1007/s00223-015-0089-z · DOI
  3. Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. https://doi.org/10.1007/s00198-012-2074-y · DOI · Paper page
  4. Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM, van Onzenoort H, Leufkens HG, Bijlsma JW, de Vries F (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26:1831–1840. https://doi.org/10.1007/s00198-015-3084-3 · DOI
  5. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in the Netherlands. Osteoporos Int 22:1537–1546. https://doi.org/10.1007/s00198-010-1372-5 · DOI
  6. Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https://doi.org/10.1136/bmjopen-2018-027049 · DOI · Paper page
  7. Hiligsmann M, Rabenda V, Gathon HJ et al (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–210. https://doi.org/10.1007/s00223-009-9329-4 · DOI
  8. Ross S, Samuels E, Gairy K et al (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Heal 14:571–581. https://doi.org/10.1016/j.jval.2010.11.010 · DOI
  9. Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29:2623–2637. https://doi.org/10.1007/s00198-018-4759-3 · DOI · Paper page
  10. Hiligsmann M, Salas M, Hughes DA et al (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907–2918. https://doi.org/10.1007/s00198-013-2364-z · DOI
  11. Kini V, Ho PM (2018) Interventions to improve medication adherence: a review. JAMA 320:2461–2473. https://doi.org/10.1001/jama.2018.19271 · DOI · Paper page
  12. Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal. Osteoporos Int:1–11. https://doi.org/10.1007/s00198-019-05104-5 · DOI
  13. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:1–6. https://doi.org/10.1371/journal.pmed.1000097 · DOI · Paper page
  14. Lehane E, McCarthy G (2009) Medication non-adherence—exploring the conceptual mire. Int J Nurs Pract 15:25–31. https://doi.org/10.1111/j.1440-172X.2008.01722.x · DOI · Paper page
  15. Ganda K, Schaffer A, Pearson S, Seibel MJ (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345–1355. https://doi.org/10.1007/s00198-013-2610-4 · DOI
  16. Ducoulombier V, Luraschi H, Forzy G et al (2015) Contribution of phone follow-up to improved adherence to oral osteoporosis treatment. Am J Pharm Benefits 7:e81–e89 https://ajmc.s3.amazonaws.com/_media/_pdf/AJPB_0506_2015_Ducoulombier(final).pdf
  17. Tamechika S-Y, Sasaki K, Hayami Y et al (2018) Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. Arch Osteoporos 13:67. https://doi.org/10.1007/s11657-018-0451-7 · DOI
  18. Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, Wright NC, Jones MP, Saag KG, PAADRN Investigators (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513–3524. https://doi.org/10.1007/s00198-016-3681-9 · DOI
  19. Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, Allison JJ, Anderson FA, Wyman A, Greenspan SL, LaCroix A, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Curtis JR, Warriner AH, Wright NC, Saag KG (2018) Evaluation of a multimodal, direct-to-patient educational intervention targeting barriers to osteoporosis care: a randomized clinical trial. J Bone Miner Res 33:763–772. https://doi.org/10.1002/jbmr.3425 · DOI
  20. van den Berg P, van Haard PMM, van der Veer E et al (2018) A dedicated fracture liaison service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates. Osteoporos Int 29:813–824. https://doi.org/10.1007/s00198-017-4340-5 · DOI
  21. Bianchi ML, Duca P, Vai S, Guglielmi G, Viti R, Battista C, Scillitani A, Muscarella S, Luisetto G, Camozzi V, Nuti R, Caffarelli C, Gonnelli S, Albanese C, de Tullio V, Isaia G, D'Amelio P, Broggi F, Croci M (2015) Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int 26:1629–1638. https://doi.org/10.1007/s00198-015-3038-9 · DOI
  22. LeBlanc A, Wang AT, Wyatt K, Branda ME, Shah ND, van Houten H, Pencille L, Wermers R, Montori VM (2015) Encounter decision aid vs. clinical decision support or usual care to support patient-centered treatment decisions in osteoporosis: the osteoporosis choice randomized trial II. PLoS One 10:e0128063. https://doi.org/10.1371/journal.pone.0128063 · DOI · Paper page
  23. Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G (2013) Priming primary care physicians to treat osteoporosis after a fragility fracture: an integrated multidisciplinary approach. J Rheumatol 40:703–711. https://doi.org/10.3899/jrheum.120908 · DOI
  24. Tüzün Ş, Akyüz G, Eskiyurt N, Memiş A, Kuran B, İçağasıoğlu A, Sarpel T, Özdemir F, Özgirgin N, Günaydın R, Cakçı A, Yurtkuran M (2013) Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study. Int J Med Sci 10:1880–1887. https://doi.org/10.7150/ijms.5359 · DOI
  25. Gonnelli S, Caffarelli C, Rossi S, di Munno O, Malavolta N, Isaia G, Muratore M, D'Avola G, Gatto S, Minisola G, Nuti R (2016) How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study. Aging Clin Exp Res 28:459–468. https://doi.org/10.1007/s40520-016-0538-1 · DOI
  26. Oral A, Lorenc R (2015) Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study. Acta Orthop Traumatol Turc 49:67–74
  27. Stuurman-Bieze AGG, Hiddink EG, Van Boven JFM (2014) Proactive pharmaceutical care interventions decrease patients’ nonadherence to osteoporosis medication. Osteoporos Int 25:1807–1812. https://doi.org/10.1007/s00198-014-2659-8 · DOI
  28. Seuffert P, Sagebien CA, McDonnell M (2016) Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos 11:1–6. https://doi.org/10.1007/s11657-016-0262-7 · DOI
  29. Beaton DE, Mamdani M, Zheng H, Jaglal S, Cadarette SM, Bogoch ER, Sale JEM, Sujic R, Jain R, Ontario Osteoporosis Strategy Fracture Clinic Screening Program Evaluation Team (2017) Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program: an interrupted time series analysis. Medicine (Baltimore) 96:e9012. https://doi.org/10.1097/MD.0000000000009012 · DOI
  30. Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54. https://doi.org/10.1016/j.bone.2013.10.006 · DOI · Paper page
  31. Edmonds SW, Wolinsky FD, Christensen AJ et al (2013) The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health. Contemp Clin Trials 34:90–100. https://doi.org/10.1016/j.cct.2012.10.002 · DOI
  32. Jensen AL, Lomborg K, Wind G et al (2014) Effectiveness and characteristics of multifaceted osteoporosis group education-a systematic review. Osteoporos Int 25:1209–1224. https://doi.org/10.1007/s00198-013-2573-5 · DOI
  33. Solomon DH, Iversen MD, Avorn J et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172:477–483. https://doi.org/10.1001/archinternmed.2011.1977 · DOI · Paper page
  34. Morfeld J-C, Vennedey V, Müller D, Pieper D, Stock S (2017) Patient education in osteoporosis prevention: a systematic review focusing on methodological quality of randomised controlled trials. Osteoporos Int 28:1779–1803. https://doi.org/10.1007/s00198-017-3946-y · DOI
  35. Presley B, Groot W, Pavlova M (2018) Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis. Res Soc Adm Pharm:1–11. https://doi.org/10.1016/j.sapharm.2018.09.021 · DOI · Paper page
  36. Seng EK, Rains JA, Nicholson RA, Lipton RB (2015) Improving medication adherence in migraine treatment. Curr Pain Headache Rep 19:1–7. https://doi.org/10.1007/s11916-015-0498-8 · DOI
  37. Bowers BL, Drew AM, Verry C (2018) Impact of pharmacist-physician collaboration on osteoporosis treatment rates. Ann Pharmacother 52:876–883. https://doi.org/10.1177/1060028018770622 · DOI
  38. Chow S (2017) Nurse practitioner fracture liaison role: a concept analysis. Orthop Nurs 36:385–391. https://doi.org/10.1097/NOR.0000000000000399 · DOI
  39. Toh LS, Lai PSM, Othman S, Wong KT, Low BY, Anderson C (2017) An analysis of inter-professional collaboration in osteoporosis screening at a primary care level using the D’Amour model. Res Soc Adm Pharm 13:1142–1150. https://doi.org/10.1016/j.sapharm.2016.10.004 · DOI
  40. Tan ECK, George J, Stewart K, Elliott RA (2014) Improving osteoporosis management in general practice: a pharmacist-led drug use evaluation program. Drugs Aging 31:703–709. https://doi.org/10.1007/s40266-014-0194-0 · DOI

Cited by

See all 101

Metadata

Authors
On behalf of the European Society for Clinical and Economic Aspect of Osteoporosis, O. A. M. D. (., Cornelissen, D., de Kunder, S., Si, L., Reginster, J.-Y., Evers, S., Boonen, A., & Hiligsmann, M.
Venue
Osteoporosis International
Published
2020-05-01
Volume
31
Issue
9
Pages
1645-1669
ISSN
  • 0937-941X (ISSN-L)
  • 1433-2965
OpenAlex
W3023298491
Cited by
101
References
8
FWCI
3.12
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • ZonMw (848016001)
  • European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (Not applicable)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. https://app.cochat.ai/papers/10.1007/s00198-020-05378-0
The paper
On behalf of the European Society for Clinical and Economic Aspect of Osteoporosis, O. A. M. D. (., Cornelissen, D., de Kunder, S., Si, L., Reginster, J.-Y., Evers, S., Boonen, A., & Hiligsmann, M. (2020). Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporosis International. https://doi.org/10.1007/s00198-020-05378-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.